The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 296.00
Bid: 295.00
Ask: 299.00
Change: 0.00 (0.00%)
Spread: 4.00 (1.356%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 296.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: JD Sports backs outlook; Spirent accepts new offer

Thu, 28th Mar 2024 08:08

(Alliance News) - Stocks in London traded higher early on Thursday in the final trading day of a holiday-shortened week, despite some hawkish words from a US central banker.

It is also despite unrevised numbers from the Office for National Statistics confirming the UK entered a technical recession in the fourth quarter of 2024.

"The only thing that investors need is the Federal Reserve rate cut dream to stay alive for the June meeting. And for now, that's the case. Activity on Fed funds futures gives around 64% chance for a June rate cut," said Swissquote Bank analyst Ipek Ozkardeskaya.

"But note that, this probability was around 75% last week and it's coming lower as many investors think that the Fed won't be able to cut the rates with robust growth and bumpy inflation. And indeed, the US latest GDP update is due today and is expected to confirm an above 3% growth for the US economy in the last quarter of last year, down from almost 5% printed a quarter earlier. These levels don’t call for an imminent Fed cut."

In early corporate news, JD Sports said it outperformed the sportswear market in its full-year, with like-for-like sales growing.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: up 0.3% at 7,955.13

----------

Hang Seng: up 1.1% at 16,564.84

Nikkei 225: closed down 1.5% at 40,168.07

S&P/ASX 200: closed up 1.0% at 7,896.90

----------

DJIA: closed up 477.75 points, 1.2%, at 39,760.08

S&P 500: closed up 44.91 points, 0.9%, at 5,248.49

Nasdaq Composite: closed up 83.82 points, 0.5%, to 16,399.52

----------

EUR: down at USD1.0802 (USD1.0823)

GBP: down at USD1.2615 (USD1.2630)

USD: up at JPY151.38 (JPY151.35)

Gold: up at USD2,193.16 per ounce (USD2,190.33)

(Brent): up at USD85.66 a barrel (USD85.41)

(changes since previous London equities close)

----------

ECONOMICS

----------

Thursday's key economic events still to come:

08:55 GMT Germany unemployment

09:00 GMT eurozone money supply

12:30 GMT US GDP

12:30 GMT US initial jobless claims

14:00 GMT US pending home sales

14:00 GMT US Michigan consumer sentiment index

15:00 GMT US Kansas City Fed manufacturing activity

----------

The UK slipped into a technical recession in the fourth quarter of 2023, numbers from the Office for National Statistics confirmed on Thursday. UK gross domestic product slumped 0.3% in the three months to December from a quarter earlier, unchanged from initial ONS numbers provided in February. The UK economy had declined 0.1% quarter-on-quarter in the third-quarter of 2023. It means the UK has entered a technical recession at the end of last year, which is generally defined as two successive quarterly falls in gross domestic product. In output terms for the fourth quarter, the ONS said there were falls in all three main sectors: services down 0.1%, production down 1.1% and construction output down 0.9%. Meanwhile, in expenditure terms, there was a fall in the volume of net trade, household consumption and gross capital formation, according to the ONS, partially offset by an increase in government consumption.

----------

The US Federal Reserve should either scale back or delay its interest rate cuts in response to "disappointing" inflation data, a senior Federal Reserve official said. "In my view, it is appropriate to reduce the overall number of rate cuts or push them further into the future in response to the recent data," Fed Governor Christopher Waller told a conference in New York. "Shorter-term inflation measures are now telling me that progress [in reducing inflation] has slowed and may have stalled. But we will need more data to know that," he added. "I see economic output and the labour market showing continued strength, while progress in reducing inflation has slowed," Waller said. "Because of these signs, I see no rush in taking the step of beginning to ease monetary policy," he continued.

----------

BROKER RATING CHANGES

----------

Jefferies cuts Diploma to 'hold' (buy) - price target 3,950 (3,750) pence

----------

Exane BNP cuts Aviva to 'underperform' ('neutral') - target 420 (445) pence

----------

Exane BNP cuts Legal & General to 'neutral' ('outperform') - target 270 (280) pence

----------

COMPANIES - FTSE 100

----------

Retailer JD Sports said it outperformed the sportswear market in the 53 weeks that ended February 3. It said like-for-like sales rose 4.2% on-year and up 8.4% organically on a constant currency basis, while total sales grew 3.6% to around GBP10.5 billion. It expects pretax profit to be in line with its guided range of GBP915 million to GBP935 million, down from GBP991.4 million a year earlier. "We made good strategic progress, opening 215 new JD stores, and focusing our effort on developing JD and enhancing EPS through taking full control of ISRG and MIG," said Chief Executive Officer Regis Schultz. It outlined its initial financial 2025 profit forecast of GBP900 million to GBP980 million, while saying trading in the new financial year-to-date is in line with its expectations after seven weeks. Schultz continued: "Looking ahead, the current trading environment remains challenging due to less product innovation and elevated promotional activity, especially online. We anticipate trading conditions will improve as we move through the year, helped by a busy sporting summer and softer comparatives with last year."

----------

The UK Competition & Markets Authority decided not to refer the planned acquisition by FTSE 100-listed insurer Aviva of AIG's life-insurance and retirement-services division AIG Life to a phase 2 investigation. The UK competition watchdog said this decision was based on the information currently available and that a further announcement on the decision will be made "as soon as is reasonably practicable". In February, the CMA said it was investigating the deal, saying it could reduce competition in the UK services sector.

----------

COMPANIES - FTSE 250

----------

Automated test and assurance solutions provider Spirent said it agreed to a GBP1.16 billion takeover from Keysight Technologies. Spirent said the offer was superior to Viavi's existing GBP1.01 billion bid. The latest offer rates Spirent at 201.5 pence per share, 199.0p in cash and 2.5p in a special dividend. Spirent Chair Bill Thomas commented: "The board of Spirent is pleased to recommend Keysight's cash offer for Spirent, which is an increase of 15% to the Viavi proposal." Chief Executive Officer Eric Updyke added: "Keysight's offer for Spirent will provide further opportunities for our employees and strengthens our customer offering, given Keysight's technology expertise, capabilities and robust global platform with its breadth and depth of industry-leading solutions."

----------

OTHER COMPANIES

----------

Cancer and immunological diseases treatments developer Hutchmed said its supplemental new drug application for savolitinib has been accepted for review by the China National Medical Products Administration. If accepted, the new label indication for savolitinib will be expanded to include treatment-naive patients, those that have not received any treatment, in China. Savolitinib is a treatment for adult patients with locally advanced or metastatic non-small cell lung cancer. It had previously been granted conditional approval in China. "More than a third of the world's lung cancer patients are in China," Hutchmed noted.

----------

Troubled utility Thames Water has said its shareholders will not be injecting the first GBP500 million of funding that was agreed last summer into the group as industry regulations make its business plan "uninvestible". Thames Water – the UK's biggest water supplier with 15 million households across London and the South East – said the funding plan drawn up last July was subject to conditions, including a business plan that is supported by "appropriate regulatory arrangements". It said the regulations being imposed by industry watchdog Ofwat "make the PR24 plan "uninvestible", and as a result the shareholder support letter from last July "has not been satisfied".

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
3 Apr 2019 12:58

Gama Aviation Appoints Managing Director Of Major Shareholder As Chair

LONDON (Alliance News) - Gama Aviation PLC on Wednesday said it has selected the managing director of major shareholder Hutchison Whampoa China Ltd as its new chair.Shares in business firm

Read more
29 Mar 2019 09:16

Hutchison China MediTech Surufatinib Cancer Study Doses First Patient

LONDON (Alliance News) - Biopharmaceutical firm Hutchison China MediTech Ltd on Friday said it has begun a study of cancer drug surufatinib in patients with advanced biliary tract biliary tract by

Read more
11 Mar 2019 11:54

Hutchison loss widens as China legislation hampers revenue

(Sharecast News) - Hutchison China Meditech on Monday reported a drop in sales and increased annual loss after the implementation of new government policy in China.

Read more
11 Mar 2019 08:45

Hutchison China Meditech 2018 Loss Widens On New Government Policy

LONDON (Alliance News) - Hutchison China Meditech Ltd on Monday said its loss widened in 2018 as sales decreased following an implementation of new government policy in China.The company to

Read more
29 Nov 2018 12:17

Hutchison Chi-Med enters four new drug test collaborations

(Sharecast News) - Hutchison China MediTech, doing business as Chi-Med, has entered into four collaboration agreements to evaluate the safety, tolerability and efficacy of its 'surufatinib' (HMPL-012 or sulfatinib) and 'fruquintinib' products, in combination with checkpoint inhibitors.

Read more
26 Nov 2018 08:35

Hutchison China Meditech Starts Fruquintinib Capsules Sales In China

LONDON (Alliance News) - Hutchison China Meditech Ltd on Monday said it launched fruquintinib capsules Elunate with the initiation of product sales in China.Elunate is used for the of with

Read more
19 Nov 2018 19:02

SVM UK Emerging Fund Beats Benchmark With Three Key Holdings

LONDON (Alliance News) - SVM UK Emerging Fund PLC on Monday said it had outpaced its benchmark in its most recent half year due to strong performances from three key holdings.As at 30, the

Read more
18 Oct 2018 10:09

Hutchison China Meditech Starts Phase I Study For Leukemia In China

LONDON (Alliance News) - Hutchison China Meditech Ltd said Thursday it commenced a phase I study of HMPL-523 to treat elderly patients with acute myeloid leukemia in China.The aim of the is

Read more
5 Sep 2018 08:28

Hutchison Gains Fruquintinib Capsules Approval As Cancer Drug In China

LONDON (Alliance News) - Hutchison China Meditech Ltd said Wednesday it gained Chinese approval for its Fruquintinib capsules to be used as treatment for metastatic colorectal cancer.The of

Read more
27 Jul 2018 08:54

Hutchinson China Meditech Swings To Net Loss, Ups Annual Loss Estimate

LONDON (Alliance News) - Hutchison China Meditech Ltd on Friday raised its annual loss estimate by USD20 million after swinging to an interim net loss.For the six months to June 30, the a a

Read more
20 Jul 2018 15:50

UK Earnings, Trading Statements Calendar - Next 7 Days

Monday 23 July Ryanair HoldingsQ1 ResultsAscentialHalf Year Retail GroupHalf 24

Read more
4 Jun 2018 11:11

Hutchison China Cancer Trial Shows Clinically Meaningful Benefits

LONDON (Alliance News) - Biopharmaceutical company Hutchison China MediTech Ltd said Monday patients in its FRESCO Phase III study "demonstrated a statistically significant and clinically at

Read more
20 Apr 2018 15:00

UK Shareholder Meetings Calendar - Next 7 Days

Monday 23 AprilForeign & Colonial Investment Trust BioquellMicrogenHgCapital

Read more
12 Mar 2018 08:53

Hutchison China Meditech 2017 Loss Widens Amid Rising Research Costs

LONDON (Alliance News) - China-focused drug developer and distributor Hutchison China Meditech PLC said Monday annual losses widened due to increased and

Read more
6 Mar 2018 09:44

Hutchison China Meditech Begins New Study For Epitinib Treatment

LONDON (Alliance News) - Pharmaceutical firm Hutchison China Meditech Ltd has started a phase Ib/II proof-of-concept study for its proposed brain cancer treatment is being in

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.